UBS: Novo Nordisk Wegovy Pill Shows Early US Uptake; Medicare, EU 7.2mg Could Impact

Wegovy pill shows early uptake in U.S. prescriptions, UBS finds

UBS analysts led by Matthew Weston report that new‑to‑brand prescription (NBRx) trends for Novo Nordisk’s Wegovy are “strong,” with initial data through Feb. 6, 2026 showing encouraging starter‑dose momentum for the newly launched oral formulation. The bank’s charts indicate a meaningful share of pill NBRx relative to total prescriptions (TRx), and a high ratio of pill starter‑dose NBRx to total NBRx that suggests limited cannibalisation of established Wegovy pen volumes at this early stage. UBS also notes an uptick in pen NBRx at the start of the year, pointing to simultaneous interest in both delivery formats among prescribers.

Analysts stress that durability of the pill launch depends on monitoring both starter‑dose NBRx and total TRx over coming months to capture refill behaviour and conversion to maintenance therapy. They identify geography and specialty adoption patterns — for example, primary care versus endocrinology — as important real‑world indicators of sustained patient uptake. UBS flags Medicare coverage beginning in July as a potential inflection point that could materially affect access, payer dynamics and longer‑term prescribing patterns for obesity GLP‑1s.

The competitive and regulatory backdrop shapes modelling for volume, pricing and market share through 2026 and beyond. The European Commission’s clearance for a higher 7.2 mg Wegovy maintenance dose reinforces demand for semaglutide‑based therapies and creates a near‑term product development catalyst for Novo. UBS points to later‑year focus items including the planned high‑dose Wegovy 7.2 mg launch and competitive pressure from Lilly’s oral GLP‑1 candidate orforglipron, with a UBS note on Lilly due in April. Together, these elements inform expectations for label updates, refill rates and payer reactions that will determine revenue trajectories.

European approval for higher Wegovy maintenance dose

Separately, regulators in Europe clear Novo Nordisk to use a 7.2 mg maintenance dose of Wegovy, a step UBS says is likely to boost semaglutide demand and expand treatment options for clinicians managing obesity across the region.

Telehealth expansion intersects obesity drug access

The recent public friction between telehealth provider Hims & Hers and Novo underscores how consumer digital health platforms are reshaping access and distribution for GLP‑1 therapies. Hims & Hers’ acquisition of digital care provider Eucalyptus signals broader industry moves to integrate virtual care, prescribing workflows and cross‑border distribution — developments that may influence how GLP‑1s are delivered and monitored outside traditional specialty clinics.